查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523027

艾森曼格症候群治疗市场报告：2030 年趋势、预测与竞争分析

Eisenmenger Syndrome Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

艾森曼格症候群治疗的趋势与预测

预计 2024 年至 2030 年，全球艾森曼格氏症治疗市场将以 5.8% 的复合年增长率成长。该市场的主要驱动因素是受艾森曼格症候群影响的患者数量不断增加，以及对先进药物开发相关研发活动的日益关注。全球艾森曼格症候群治疗市场前景广阔，医院药局、线上药局和零售药局市场充满机会。

艾森曼格症候群的分段治疗

本研究按药物类型、分销管道和地区对全球艾森曼格综合征治疗进行了预测。

艾森曼格症候群治疗市场洞察

Lucintel 预测，内皮素受体拮抗剂预计将在预测期内实现最高增长，因为它们对各种併发症的治疗具有广泛的影响，而且成本可能较低。

在这个市场中，医院药房预计将在预测期内实现最高成长。

由于慢性病的增加和先进医疗技术的高采用率，北美在预测期内仍将是最大的地区。

常问问题

Q1.市场成长预测是多少：

A1. 2024 年至 2030 年，全球艾森曼格氏症候群治疗市场预计将以 5.8% 的复合年增长率成长。

Q2. 影响市场成长的主要驱动因素是：

A2. 该市场的主要驱动力是受艾森曼格氏症候群影响的患者数量不断增加，以及对与先进药物开发相关的研发活动的日益关注。

Q3.市场的主要细分市场是：

A3. 艾森曼格症候群治疗市场未来性广阔，医院药局、网路药局和零售药局市场充满机会。

Q4.市场的主要企业是：

A4. 生产艾森曼格氏症候群治疗药物的主要企业如下：

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Q5.未来最大的细分市场是什么？

A5.Lucintel 预测，内皮素受体拮抗剂将在预测期内表现出最高的成长，因为它们对各种併发症的治疗具有广泛的影响，而且成本可能较低。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 由于慢性病的增加和先进医疗技术的高采用率，预计北美在预测期内仍将是最大的地区。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球艾森曼格症候群治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球艾森曼格氏症候群治疗市场趋势（2018-2023）与预测（2024-2030）
  • 艾森曼格症候群治疗的全球市场（按药物类型）
    • 抗心律不整药物
    • 抗凝血物
    • 内皮素受体拮抗剂
    • 其他的
  • 按分销管道分類的全球艾森曼格症候群治疗市场
    • 医院药房
    • 网路药房
    • 零售药房

第四章 2018-2030年区域市场趋势及预测分析

  • 艾森曼格症候群治疗市场（按地区）
  • 北美艾森曼格症候群治疗市场
  • 欧洲艾森曼格症候群治疗市场
  • 亚太地区艾森曼格症候群治疗市场
  • 其他地区艾森曼格症候群治疗市场

第五章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
  • 全球艾森曼格氏症候群治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球艾森曼格症候群治疗市场的产能
    • 全球艾森曼格氏症候群治疗市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer
简介目录

Eisenmenger Syndrome Treatment Trends and Forecast

The future of the global eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets. The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Eisenmenger Syndrome Treatment by Segment

The study includes a forecast for the global eisenmenger syndrome treatment by drug type, distribution channel, and region.

Eisenmenger Syndrome Treatment Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Antiarrhythmic Agents
  • Blood Thinning Agents
  • Endothelin Receptor Antagonist
  • Others

Eisenmenger Syndrome Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Eisenmenger Syndrome Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Eisenmenger Syndrome Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies eisenmenger syndrome treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eisenmenger syndrome treatment companies profiled in this report include-

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Eisenmenger Syndrome Treatment Market Insights

Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Within this market, hospital pharmacies is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Features of the Global Eisenmenger Syndrome Treatment Market

Market Size Estimates: Eisenmenger syndrome treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Eisenmenger syndrome treatment market size by drug type, distribution channel, and region in terms of value ($B).

Regional Analysis: Eisenmenger syndrome treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, and regions for the eisenmenger syndrome treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eisenmenger syndrome treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for eisenmenger syndrome treatment market?

Answer: The global eisenmenger syndrome treatment market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the eisenmenger syndrome treatment market?

Answer: The major drivers for this market are growing number of patients suffering from eisenmenger syndrome and rising focus on r&d activities related to the development of advanced drugs.

Q3. What are the major segments for eisenmenger syndrome treatment market?

Answer: The future of the eisenmenger syndrome treatment market looks promising with opportunities in the hospital pharmacies, online pharmacies, and retail pharmacies markets.

Q4. Who are the key eisenmenger syndrome treatment market companies?

Answer: Some of the key eisenmenger syndrome treatment companies are as follows:

  • Actelion Pharmaceuticals
  • Gilead Sciences
  • Pfizer
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Novartis
  • Merck & Co
  • GlaxoSmithKline
  • Mylan
  • Bayer

Q5. Which eisenmenger syndrome treatment market segment will be the largest in future?

Answer: Lucintel forecasts that endothelin receptor antagonist is expected to witness the highest growth over the forecast period due to their broader impact on managing various complications and potentially lower cost.

Q6. In eisenmenger syndrome treatment market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing incidences of chronic diseases and higher adoption rate of advanced medical technologies in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the eisenmenger syndrome treatment market by drug type (antiarrhythmic agents, blood thinning agents, endothelin receptor antagonist, and others), distribution channel (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Eisenmenger Syndrome Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Eisenmenger Syndrome Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Eisenmenger Syndrome Treatment Market by Drug Type
    • 3.3.1: Antiarrhythmic Agents
    • 3.3.2: Blood Thinning Agents
    • 3.3.3: Endothelin Receptor Antagonist
    • 3.3.4: Others
  • 3.4: Global Eisenmenger Syndrome Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Online Pharmacies
    • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Eisenmenger Syndrome Treatment Market by Region
  • 4.2: North American Eisenmenger Syndrome Treatment Market
    • 4.2.1: North American Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.2.2: North American Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.3: European Eisenmenger Syndrome Treatment Market
    • 4.3.1: European Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.3.2: European Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.4: APAC Eisenmenger Syndrome Treatment Market
    • 4.4.1: APAC Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.4.2: APAC Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
  • 4.5: ROW Eisenmenger Syndrome Treatment Market
    • 4.5.1: ROW Eisenmenger Syndrome Treatment Market by Drug Type: Antiarrhythmic Agents, Blood Thinning Agents, Endothelin Receptor Antagonist, and Others
    • 4.5.2: ROW Eisenmenger Syndrome Treatment Market by Distribution Channel: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Eisenmenger Syndrome Treatment Market by Region
  • 6.2: Emerging Trends in the Global Eisenmenger Syndrome Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Eisenmenger Syndrome Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Eisenmenger Syndrome Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Actelion Pharmaceuticals
  • 7.2: Gilead Sciences
  • 7.3: Pfizer
  • 7.4: Teva Pharmaceutical Industries
  • 7.5: AstraZeneca
  • 7.6: Novartis
  • 7.7: Merck & Co
  • 7.8: GlaxoSmithKline
  • 7.9: Mylan
  • 7.10: Bayer